Emerging evidence of Nimotuzumab (BioMab EGFR) in Esophageal Cancers
(2-November-2012)
Safety and efficacy of anti – EGF receptor humanized monoclonal antibody Nimotuzumab in unresectable esophoageal tumors in combination with chemo-radiotherapy: Phase II clinical trial final results one quite impresive.